ArticleScientific reports2026
Identifying the shared genes and their related microRNAs, metabolites, and pathways in ischemic stroke and epilepsy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background This study aimed to identify shared genes between ischemic stroke (IS) and epilepsy and explore underlying mechanisms. Methods Transcriptomic datasets from the GEO database were analyzed using differential expression and weighted gene co-expression network analysis (WGCNA). Hub-shared genes were identified through protein-protein interaction networks, ROC analysis, and expression validation. Upstream miRNAs were predicted. Additionally, untargeted plasma metabolomics was performed on children with epilepsy and healthy controls, followed by differential metabolite analysis and metabolic pathway construction. Results WGCNA revealed 594 epilepsy-related and 2,623 IS-related DEGs, with 38 shared DEGs identified, including IL10RA, CD2, and C3AR1. These genes showed high diagnostic value, with their AUC value > 0.66 in both training and validation datasets. Additionally, hsa-let-7b-5p was predicted to target C3AR1. Metabolomics identified 139 differential metabolites, and C3AR1 was implicated in synaptic vesicle cycle, taste transduction, and nicotine addiction pathways via acetylcholine. Conclusions The shared genes, especially C3AR1 may be a key regulator in the development IS and epilepsy, showing potential as a biomarker for both diseases. However, its diagnostic efficacy requires further clinical validation. Given the complexity of these diseases, future research may focus on identifying a panel of biomarkers rather than relying on a single gene.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.